Y Intercept Hong Kong Ltd Grows Position in Indivior PLC $INDV

Y Intercept Hong Kong Ltd boosted its position in shares of Indivior PLC (NASDAQ:INDV) by 17.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,443 shares of the company’s stock after purchasing an additional 3,769 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Indivior were worth $375,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Indivior by 16.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares in the last quarter. CTC Alternative Strategies Ltd. bought a new position in shares of Indivior during the 1st quarter worth $96,000. State of New Jersey Common Pension Fund D purchased a new position in shares of Indivior during the second quarter valued at $262,000. XTX Topco Ltd increased its stake in shares of Indivior by 123.9% during the first quarter. XTX Topco Ltd now owns 50,437 shares of the company’s stock valued at $481,000 after buying an additional 27,906 shares during the period. Finally, New York State Common Retirement Fund bought a new stake in shares of Indivior in the first quarter valued at about $295,000. Institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INDV. HC Wainwright increased their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group started coverage on shares of Indivior in a report on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 price target for the company. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Craig Hallum reissued a “buy” rating and set a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Finally, Northland Securities set a $40.00 price objective on shares of Indivior in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.17.

Indivior Stock Performance

INDV stock opened at $31.34 on Friday. Indivior PLC has a one year low of $7.62 and a one year high of $32.42. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of 50.55 and a beta of 0.68. The firm has a 50-day simple moving average of $24.99 and a two-hundred day simple moving average of $18.92.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.38 by $0.34. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. The firm had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.